{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T10:07:42Z","timestamp":1775297262959,"version":"3.50.1"},"reference-count":48,"publisher":"Bentham Science Publishers Ltd.","issue":"6","funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["930761"],"award-info":[{"award-number":["930761"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2020,6,14]]},"abstract":"<jats:sec><jats:title>Aims:<\/jats:title><jats:p>Here, three liposomal formulations of DPPC\/DPPG\/Chol\/DSPE-mPEG2000 (F1), DPPC\/DPPG\/Chol (F2) and HSPC\/DPPG\/Chol\/DSPE-mPEG2000 (F3) encapsulating BTZ were prepared and characterized in terms of their size, surface charge, drug loading, and release profile. Mannitol was used as a trapping agent to entrap the BTZ inside the liposomal core. The cytotoxicity and anti-tumor activity of formulations were investigated in vitro and in vivo in mice bearing tumor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background:<\/jats:title><jats:p>Bortezomib (BTZ) is an FDA approved proteasome inhibitor for the treatment of mantle cell lymphoma and multiple myeloma. The low solubility of BTZ has been responsible for the several side effects and low therapeutic efficacy of the drug. Encapsulating BTZ in a nano drug delivery system; helps overcome such issues. Among NDDSs, liposomes are promising diagnostic and therapeutic delivery vehicles in cancer treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>Evaluating anti-tumor activity of bortezomib liposomal formulations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Data prompted us to design and develop three different liposomal formulations of BTZ based on Tm parameter, which determines liposomal stiffness. DPPC (Tm 41\u00b0C) and HSPC (Tm 55\u00b0C) lipids were chosen as variables associated with liposome rigidity. In vitro cytotoxicity assay was then carried out for the three designed liposomal formulations on C26 and B16F0, which are the colon and melanoma cancer mouse-cell lines, respectively. NIH 3T3 mouse embryonic fibroblast cell line was also used as a normal cell line. The therapeutic efficacy of these formulations was further assessed in mice tumor models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result:<\/jats:title><jats:p>MBTZ were successfully encapsulated into all the three liposomal formulations with a high entrapment efficacy of 60, 64, and 84% for F1, F2, and F3, respectively. The findings showed that liposomes mean particle diameter ranged from 103.4 to 146.8nm. In vitro cytotoxicity studies showed that liposomal-BTZ formulations had higher IC50 value in comparison to free BTZ. F2-liposomes with DPPC, having lower Tm of 41\u00b0C, showed much higher anti-tumor efficacy in mice models of C26 and B16F0 tumors compared to F3-HSPC liposomes with a Tm of 55\u00b0C. F2 formulation also enhanced mice survival compared with untreated groups, either in BALB\/c or in C57BL\/6 mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Our findings indicated that F2-DPPC-liposomal formulations prepared with Tm close to body temperature seem to be effective in reducing the side effects and increasing the therapeutic efficacy of BTZ and merits further investigation.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1871520620666200101150640","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T07:52:52Z","timestamp":1577951572000},"page":"700-708","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib"],"prefix":"10.2174","volume":"20","author":[{"given":"Mitra","family":"Korani","sequence":"first","affiliation":[{"name":"Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Nikoofal-Sahlabadi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin R.","family":"Nikpoor","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solmaz","family":"Ghaffari","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Attar","sequence":"additional","affiliation":[{"name":"Chemical Engineering Department, Engineering and Technology Faculty, Sciences and Research Branch, Islamic Azad University, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5197-6260","authenticated-orcid":true,"given":"Mohammad","family":"Mashreghi","sequence":"additional","affiliation":[{"name":"Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud R.","family":"Jaafari","sequence":"additional","affiliation":[{"name":"Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ijrobp.2008.08.050","volume":"74","author":"Kubicek G.J.","year":"2009","unstructured":"Kubicek G.J.; Werner-Wasik M.; Machtay M.; Mallon G.; Myers T.; Ramirez M.; Andrews D.; Curran W.J.; Dicker A.P.; Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 2009,74(2),433-439","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/S0268-960X(10)70003-5","volume":"24","author":"Mahindra A.","year":"2010","unstructured":"Mahindra A.; Hideshima T.; Anderson K.C.; Multiple myeloma: biology of the disease. Blood Rev 2010,24,S5-S11","journal-title":"Blood Rev"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jpba.2008.09.053","volume":"49","author":"Hsieh F.Y.","year":"2009","unstructured":"Hsieh F.Y.; Tengstrand E.; Pekol T.M.; Guerciolini R.; Miwa G.; Elucidation of potential bortezomib response markers in mutliple myeloma patients. J Pharm Biomed Anal 2009,49(1),115-122","journal-title":"J Pharm Biomed Anal"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2011.09.006","volume":"76","author":"Besse B.","year":"2012","unstructured":"Besse B.; Planchard D.; Veillard A-S.; Taillade L.; Khayat D.; Ducourtieux M.; Pignon J-P.; Lumbroso J.; Lafontaine C.; Mathiot C.; Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. Lung Cancer 2012,76(1),78-83","journal-title":"Lung Cancer"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1016\/j.juro.2012.07.108","volume":"188","author":"Sato A.","year":"2012","unstructured":"Sato A.; Asano T.; Ito K.; Asano T.; Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells. J Urol 2012,188(6),2410-2418","journal-title":"J Urol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/jcmm.12279","volume":"18","author":"Kubiczkova L.","year":"2014","unstructured":"Kubiczkova L.; Pour L.; Sedlarikova L.; Hajek R.; Sevcikova S.; Proteasome inhibitors \u2013 molecular basis and current perspectives in multiple myeloma. J Cell Mol Med 2014,18(6),947-961","journal-title":"J Cell Mol Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","volume":"17","author":"Arastu-Kapur S.","year":"2011","unstructured":"Arastu-Kapur S.; Anderl J.L.; Kraus M.; Parlati F.; Shenk K.D.; Lee S.J.; Muchamuel T.; Bennett M.K.; Driessen C.; Ball A.J.; Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011,17(9),2734-2743","journal-title":"Clin Cancer Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"T1","DOI":"10.1530\/ERC-14-0005","volume":"22","author":"Johnson D.E.","year":"2015","unstructured":"Johnson D.E.; The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. Endocr Relat Cancer 2015,22(1),T1-T17","journal-title":"Endocr Relat Cancer"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1158\/1535-7163.MCT-05-0437","volume":"5","author":"Canfield S.E.","year":"2006","unstructured":"Canfield S.E.; Zhu K.; Williams S.A.; McConkey D.J.; Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol Cancer Ther 2006,5(8),2043-2050","journal-title":"Mol Cancer Ther"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1158\/1535-7163.59.3.1","volume":"3","author":"Nawrocki S.T.","year":"2004","unstructured":"Nawrocki S.T.; Sweeney-Gotsch B.; Takamori R.; McConkey D.J.; The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004,3(1),59-70","journal-title":"Mol Cancer Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1073\/pnas.94.3.855","volume":"94","author":"Drexler H.C.A.","year":"1997","unstructured":"Drexler H.C.A.; Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 1997,94(3),855-860","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5070\/D30CV3T3F4","volume":"14","author":"Rodr\u00edguez-Mart\u00edn M.","year":"2008","unstructured":"Rodr\u00edguez-Mart\u00edn M.; S\u00e1ez-Rodr\u00edguez M.; Garc\u00eda-Bust\u00ednduy M.; Mart\u00edn-Herrera A.; Noda-Cabrera A.; Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report. Dermatol Online J 2008,14(11),14","journal-title":"Dermatol Online J"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ejpb.2008.11.010","volume":"71","author":"Maeda H.","year":"2009","unstructured":"Maeda H.; Bharate G.Y.; Daruwalla J.; Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009,71(3),409-419","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","volume":"18","author":"Niewerth D.","year":"2015","unstructured":"Niewerth D.; Jansen G.; Assaraf Y.G.; Zweegman S.; Kaspers G.J.L.; Cloos J.; Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updat 2015,18,18-35","journal-title":"Drug Resist Updat"},{"key":"ref=15","volume":"20","author":"Korani M.","year":"2019","unstructured":"Korani M.; Ghaffari S.; Attar H.; Mashreghi M.; Jaafari M.R.; Preparation and characterization of nanoliposomal bortezomib formulations and evaluation of their anti-cancer efficacy in mice bearing C26 colon carcinoma and B16F0 melanoma. Nanomedicine 2019,20","journal-title":"Nanomedicine"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1359-0294(00)00090-X","volume":"6","author":"Barenholz Y.","year":"2001","unstructured":"Barenholz Y.; Liposome application: Problems and prospects. Curr Opin Colloid Interface Sci 2001,6(1),66-77","journal-title":"Curr Opin Colloid Interface Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrd1632","volume":"4","author":"Torchilin V.P.","year":"2005","unstructured":"Torchilin V.P.; Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005,4(2),145","journal-title":"Nat Rev Drug Discov"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/BF00047468","volume":"6","author":"Jain R.K.","year":"1987","unstructured":"Jain R.K.; Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987,6(4),559-593","journal-title":"Cancer Metastasis Rev"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.bbamem.2004.03.006","volume":"1663","author":"Charrois G.J.R.","year":"2004","unstructured":"Charrois G.J.R.; Allen T.M.; Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta (BBA)- Biomembranes 2004,1663(1),167-177","journal-title":"Biochim Biophys Acta (BBA)- Biomembranes"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1126\/science.7871422","volume":"267","author":"Lasic D.D.","year":"1995","unstructured":"Lasic D.D.; Papahadjopoulos D.; Liposomes revisited. Science 1995,267(5202),1275-1276","journal-title":"Science"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/581363","author":"Stathopoulos G.P.","year":"2012","unstructured":"Stathopoulos G.P.; Boulikas T.; Lipoplatin formulation review article. J Drug Deliv 2012","journal-title":"J Drug Deliv"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ajps.2014.09.004","volume":"10","author":"Li J.","year":"2015","unstructured":"Li J.; Wang X.; Zhang T.; Wang C.; Huang Z.; Luo X.; Deng Y.; A review on phospholipids and their main applications in drug delivery systems. Asian J Pharm Sci 2015,10(2),81-98","journal-title":"Asian J Pharm Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.apsb.2019.02.010","volume":"9","author":"Wu H.","year":"2019","unstructured":"Wu H.; Yu M.; Miao Y.; He S.; Dai Z.; Song W.; Liu Y.; Song S.; Ahmad E.; Wang D.; Cholesterol-tuned liposomal membrane rigidity directs tumor penetration and anti-tumor effect. Acta Pharm Sin B 2019,9(4),858-870","journal-title":"Acta Pharm Sin B"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1002\/ange.200900111","volume":"121","author":"Huang Z.","year":"2009","unstructured":"Huang Z.; Jaafari M.R.; Szoka F.C.; Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery. Angew Chem 2009,121(23),4210-4213","journal-title":"Angew Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"15702","DOI":"10.1021\/ja8065557","volume":"130","author":"Huang Z.","year":"2008","unstructured":"Huang Z.; Szoka F.C.; Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties. J Am Chem Soc 2008,130(46),15702-15712","journal-title":"J Am Chem Soc"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ijpharm.2013.10.018","volume":"458","author":"Amin M.","year":"2013","unstructured":"Amin M.; Badiee A.; Jaafari M.R.; Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. Int J Pharm 2013,458(2),324-333","journal-title":"Int J Pharm"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1158\/1078-0432.CCR-05-1566","volume":"12","author":"Schluep T.","year":"2006","unstructured":"Schluep T.; Hwang J.; Cheng J.; Heidel J.D.; Bartlett D.W.; Hollister B.; Davis M.E.; Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res 2006,12(5),1606-1614","journal-title":"Clin Cancer Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.clon.2013.11.022","volume":"26","author":"Kouroukis C.T.","year":"2014","unstructured":"Kouroukis C.T.; Baldassarre F.G.; Haynes A.E.; Imrie K.; Reece D.E.; Cheung M.C.; Bortezomib in multiple myeloma: a practice guideline. Clin Oncol (R Coll Radiol) 2014,26(2),110-119","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S1470-2045(14)70245-1","volume":"15","author":"Cook G.","year":"2014","unstructured":"Cook G.; Williams C.; Brown J.M.; Cairns D.A.; Cavenagh J.; Snowden J.A.; Ashcroft A.J.; Fletcher M.; Parrish C.; Yong K.; High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label. Lancet Oncol 2014,15(8),874-885","journal-title":"Lancet Oncol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","volume":"120","author":"Messinger Y.H.","year":"2012","unstructured":"Messinger Y.H.; Gaynon P.S.; Sposto R.; van der Giessen J.; Eckroth E.; Malvar J.; Bostrom B.C.; Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia","journal-title":"Blood"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/pbc.24271","volume":"60","author":"Muscal J.A.","year":"2013","unstructured":"Muscal J.A.; Thompson P.A.; Horton T.M.; Ingle A.M.; Ahern C.H.; McGovern R.M.; Reid J.M.; Ames M.M.; Espinoza-Delgado I.; Weigel B.J.; A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children\u2019s Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer 2013,60(3),390-395","journal-title":"Pediatr Blood Cancer"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ncponc0555","volume":"3","author":"Caravita T.","year":"2006","unstructured":"Caravita T.; de Fabritiis P.; Palumbo A.; Amadori S.; Boccadoro M.; Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat Rev Clin Oncol 2006,3(7),374","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=33","author":"Hall D.G.","year":"2006","unstructured":"Hall D.G.; Boronic Acids: Preparation, Applications in Organic Synthesis and Medicine 2006","journal-title":"Boronic Acids: Preparation, Applications in Organic Synthesis and Medicine"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2147\/IJN.S68861","volume":"10","author":"Bozzuto G.","year":"2015","unstructured":"Bozzuto G.; Molinari A.; Liposomes as nanomedical devices. Int J Nanomedicine 2015,10,975","journal-title":"Int J Nanomedicine"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2217\/17435889.1.3.297","volume":"1","author":"Immordino M.L.","year":"2006","unstructured":"Immordino M.L.; Dosio F.; Cattel L.; Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006,1(3),297","journal-title":"Int J Nanomedicine"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ijpharm.2014.07.020","volume":"473","author":"Alavizadeh S.H.","year":"2014","unstructured":"Alavizadeh S.H.; Badiee A.; Golmohammadzadeh S.; Jaafari M.R.; The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma. Int J Pharm 2014,473(1-2),326-333","journal-title":"Int J Pharm"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.bbamem.2006.12.013","volume":"1768","author":"Dos Santos N.","year":"2007","unstructured":"Dos Santos N.; Allen C.; Doppen A-M.; Anantha M.; Cox K.A.K.; Gallagher R.C.; Karlsson G.; Edwards K.; Kenner G.; Samuels L.; Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta (BBA)- Biomembranes 2007,1768(6),1367-1377","journal-title":"Biochim Biophys Acta (BBA)- Biomembranes"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/pharmaceutics9020012","volume":"9","author":"Bulbake U.","year":"2017","unstructured":"Bulbake U.; Doppalapudi S.; Kommineni N.; Khan W.; Liposomal formulations in clinical use: An updated review. Pharmaceutics 2017,9(2),12","journal-title":"Pharmaceutics"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jconrel.2015.05.286","volume":"211","author":"Zuccari G.","year":"2015","unstructured":"Zuccari G.; Milelli A.; Pastorino F.; Loi M.; Petretto A.; Parise A.; Marchetti C.; Minarini A.; Cilli M.; Emionite L.; Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma. J Control Release 2015,211,44-52","journal-title":"J Control Release"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"5282","DOI":"10.1021\/jm500352v","volume":"57","author":"Ashley J.D.","year":"2014","unstructured":"Ashley J.D.; Stefanick J.F.; Schroeder V.A.; Suckow M.A.; Kiziltepe T.; Bilgicer B.; Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo. J Med Chem 2014,57(12),5282-5292","journal-title":"J Med Chem"},{"key":"ref=41","first-page":"224","volume":"63","author":"Butu A.","year":"2015","unstructured":"Butu A.; Rodino S.; Golea D.; Butu M.; Butnariu M.; Negoescu C.; Dinu Pirvu C-E.; Liposomal nanodelivery system for proteasome inhibitor anticancer drug bortezomib. Farmacia 2015,63(2),224-229","journal-title":"Farmacia"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jconrel.2008.04.004","volume":"129","author":"Martinez M.","year":"2008","unstructured":"Martinez M.; Rathbone M.; Burgess D.; Huynh M.; In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting. J Control Release Off J Control Release Soc 2008,129(2),79","journal-title":"J Control Release Off J Control Release Soc"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/jps.23795","volume":"103","author":"Cipolla D.","year":"2014","unstructured":"Cipolla D.; Wu H.; Eastman S.; Redelmeier T.; Gonda I.; Chan H.; Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation. J Pharm Sci 2014,103(1),314-327","journal-title":"J Pharm Sci"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1126\/science.1095833","volume":"303","author":"Allen T.M.","year":"2004","unstructured":"Allen T.M.; Cullis P.R.; Drug delivery systems: entering the mainstream. Science 2004,303(5665),1818-1822","journal-title":"Science"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ijpharm.2018.09.047","volume":"551","author":"Farzaneh H.","year":"2018","unstructured":"Farzaneh H.; Ebrahimi Nik M.; Mashreghi M.; Saberi Z.; Jaafari M.R.; Teymouri M.; A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy. Int J Pharm 2018,551(1-2),300-308","journal-title":"Int J Pharm"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.22159\/ijap.2018v10i5.27568","volume":"10","author":"Sebak A.A.","year":"2018","unstructured":"Sebak A.A.; Limitations of pegylated nanocarriers: Unfavourable physicochemical properties, biodistribution patterns and cellular and subcellular fates. Int J Appl Pharm 2018,10(5),6-12","journal-title":"Int J Appl Pharm"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"23450","DOI":"10.1074\/jbc.M709387200","volume":"283","author":"El-Sayed A.","year":"2008","unstructured":"El-Sayed A.; Khalil I.A.; Kogure K.; Futaki S.; Harashima H.; Octaarginine- and octalysine-modified nanoparticles have different modes of endosomal escape. J Biol Chem 2008,283(34),23450-23461","journal-title":"J Biol Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.2147\/IJN.S168053","volume":"13","author":"Kalaydina R-V.","year":"2018","unstructured":"Kalaydina R-V.; Bajwa K.; Qorri B.; Decarlo A.; Szewczuk M.R.; Recent advances in \u201csmart\u201d delivery systems for extended drug release in cancer therapy. Int J Nanomedicine 2018,13,4727","journal-title":"Int J Nanomedicine"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/177981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T18:28:52Z","timestamp":1665340132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/177981\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,14]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,14]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520620666200101150640","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,14]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-07-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}